Tag: date

Austin, TX, July 19, 2025 (GLOBE NEWSWIRE) -- Author and tech expert James Altucher has published a new account detailing what he believes may be the most important development in Elon Musk’s career since the founding of SpaceX and Tesla.

Tech Expert and Former Hedge Fund Manager James Altucher Releases Detailed Brief Uncovering Three Overlooked Clues Surrounding Starlink and a Potential Public Event

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In XPLR Infrastructure (XIFR) To Contact Him Directly To Discuss Their Options

Retail investors gain first-of-its-kind on‑chain access to early‑stage private equity in nuclear micro‑reactors

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Thomson Reuters Corp (Nasdaq: TRI), will become a component of the Nasdaq-100 Index^® (Nasdaq: NDX^®) and the Nasdaq-100 Equal Weighted™ Index (Nasdaq: NDXE™) prior to market open on Monday, July 28, 2025. Thomson Reuters Corp will replace ANSYS, Inc. (Nasdaq: ANSS) in the Nasdaq-100 Index^® and the Nasdaq-100 Equal Weighted™ Index.

SAN FRANCISCO, July 18, 2025 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), the nation’s leading provider of clean energy as a subscription service, today announced it has priced a securitization of leases and power purchase agreements. The securitization is Sunrun’s fourteenth public securitization since 2015 and third issuance in 2025.

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose”) is pleased to announce distributions for the month of July 2025 for its open-end exchange traded funds and closed-end funds (“the Funds”).

TORONTO, 18 juill. 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (« Purpose ») a le plaisir d’annoncer des distributions pour le mois de de juillet 2025 pour ses fonds négociés en bourse à capital variable et ses fonds à capital fixe (les « Fonds »).

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance’s common stock to 20 new, non-executive employees.